Skip to main content
Virbac logo

Virbac — Investor Relations & Filings

Ticker · FR000 ISIN · FR0000031577 LEI · 969500QQ1X5XHG649644 PA Manufacturing
Open in API
Filings indexed 975 across all filing types
Latest filing 2011-11-15 Interim / Quarterly Rep…
Country FR France
Listing PA FR000

About Virbac

https://corporate.virbac.com/home.html

Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Founded in 1968 by a veterinarian, the company provides veterinarians, farmers, and pet owners with a comprehensive range of products and services. Its portfolio of innovative solutions covers the majority of animal species and diseases, with a focus on both companion and farm animals. Key product areas include vaccines, dermatology, parasite control, dental care, nutrition, and diagnostics. Through its international R&D network, Virbac develops solutions to prevent, diagnose, and treat animal pathologies, contributing to animal welfare and supporting sustainable farming.

Recent filings

Filing Released Lang Actions
Quarterly financial report - September 2011
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly report as of September 30, 2011' and contains substantive financial data, including consolidated sales figures, debt analysis, and turnover breakdowns by business segment. It provides a detailed management discussion of the financial situation and business trends for the nine-month period. Since it contains actual financial statements and analysis rather than just an announcement or certification, it is classified as an Interim/Quarterly Report. 9M 2011
2011-11-15 English
Declaration of the number of shares and voting rights as of Oct. 2011
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is explicitly titled 'DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS' and references Article 223-16 of the French Financial Market Authority (AMF) regulations. It provides a table detailing the total number of shares and the total number of voting rights as of a specific date (October 31, 2011). This content directly relates to the official declaration of voting rights and share capital structure, which aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an AGM presentation, a full annual report, or a management change announcement.
2011-11-15 English
Déclaration d'actions et de droits de vote au 31 Octobre 2011
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document title is "DECLARATION D'ACTIONS ET DE DROITS DE VOTE" (Declaration of Shares and Voting Rights). It explicitly references Article 223-16 of the General Regulation of the AMF (Autorité des Marchés Financiers) and provides a table detailing the total number of shares and the total gross and net voting rights as of a specific date (October 31, 2011). This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements.
2011-11-15 French
VIRBAC ENTERS IN A NEW TECHNOLOGY ALLIANCE
Regulatory Filings Classification · 95% confidence The document is a press release dated November 14, 2011, announcing a strategic alliance and joint venture between Virbac and Schweitzer Biotech Company (SBC) concerning food-producing animal vaccines. This announcement details a corporate transaction (M&A/Partnership) rather than routine financial reporting (10-K, ER, IR) or a general regulatory filing. Among the specific categories, 'M&A Activity (Code: TAR)' is defined as 'Announcements and documents related to merger proposals or takeover bids.' A strategic alliance leading to a joint venture fits best under this category as it represents a significant corporate transaction affecting the company's structure and operations, even if it is not a full merger or acquisition.
2011-11-14 English
VIRBAC noue une nouvelle Alliance technologique
M&A Activity Classification · 98% confidence The document is a press release dated November 14, 2011, announcing a strategic alliance (joint venture) between Virbac and Schweitzer Biotech Company (SBC) in the field of animal vaccines. This announcement details a corporate transaction involving the creation of a new entity and the exchange of assets/expertise. This type of corporate action, specifically related to mergers, acquisitions, or significant strategic partnerships, aligns best with the 'M&A Activity' category (TAR). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it describes a specific corporate transaction.
2011-11-14 French
Virbac : Continuation of the growth trend in the 3rd quarter
Earnings Release Classification · 98% confidence The document is a public release dated October 18th, 2011, detailing sales figures for the third quarter and year-to-date performance (nine months). It provides key financial highlights, growth rates (organic, constant exchange rates), and segment breakdowns. This structure—a brief announcement of period results rather than the comprehensive, audited report (10-K) or a detailed management discussion (MDA)—is characteristic of an Earnings Release (ER). It is too detailed for a simple RPA but lacks the depth of an IR or 10-K. 9M 2011
2011-10-18 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.